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ABSTRACT
Introduction: Faecal incontinence is a distressing
condition with recurrent uncontrolled passage of
faecal material. Although faecal incontinence may
cause psychological depression and social isolation,
previous treatments have been limited. Recently,
regenerative treatment has been developed using
mesenchymal stem cells. Especially, there are
possibilities that adipose-tissue-derived stem cells can
be effective to treat a degenerated anal sphincter that
is causing faecal incontinence. Therefore, this study
aimed to investigate the safety and efficacy of using
allogeneic-adipose-derived mesenchymal stem cells in
the treatment of the anal sphincter of patients with
faecal incontinence.
Methods and analysis: This study is a randomised,
prospective, dose escalation, placebo-controlled,
single-blinded, single-centre trial with two parallel
groups. The safety test is performed by an injection of
allogeneic-adipose-derived mesenchymal stem cells
(ALLO-ASCs) into the anal sphincter with dose
escalation (3×107, 6×107 and 9×107 cells,
sequentially). After confirming the safety of the stem
cells, an efficacy test is performed by this dose in the
experimental group. The experimental group will
receive ALLO-ASCs mixed with fibrin glue into the
anal sphincter, and the placebo group will receive
0.9% normal saline injection mixed with fibrin glue.
The primary end point is to assess the safety of
ALLO-ASCs after the injection into the anal sphincter,
and the secondary end point is to compare the
efficacy of ALLO-ASC injection with fibrin glue in
patients with faecal incontinence.
Ethics and dissemination: The study protocol was
approved by the Ministry of Food and Drug Safety and
the Ministry of Health & Welfare, in the Republic of
Korea. The informed consent form was approved by
the institutional review board of Gangnam Severance
Hospital (IRB approval number 3-2014-0271).
Dissemination of the results will be presented at a
conference and in peer-reviewed publications.
Trial registration number: NCT02384499; Pre-
results.
INTRODUCTION
Faecal incontinence is a distressing condition
with recurrent uncontrolled passage of faecal
material. It is deﬁned as an unintentional
loss of stool or ﬂatus for at least 1 month,
associated with faecal impaction, diarrhoea
or non-structural anal sphincter dysfunction
in a patient with more than 4 years of devel-
opmental age.1 2 Although it is a benign
non-functional symptom, patients may have
psychological depression as well as be con-
ﬁned to limited social activities. The preva-
lence of faecal incontinence is estimated to
be about 1.5% in the overall population and
18% in people more than 65 years old.3
Although it tends to be underestimated
because of concealment and embarrassment,
faecal incontinence is the second most
common cause of institutionalisation with
increasing rates in the elderly.4
There are multifactorial causes of faecal
incontinence related to anatomical or
Strengths and limitations of this study
▪ This study is the first randomised clinical trial for
the treatment of faecal incontinence using
allogeneic-adipose-derived mesenchymal stem
cells (ALLO-ASCs), as a phase I study.
▪ The results of this study are expected to deter-
mine a safe dose of ALLO-ASCs injection into
the anal sphincter by dose-escalation.
▪ The clinical outcomes and efficacy after
ALLO-ASC injection are evaluated objectively by
Wexner score, anorectal manometry and endor-
ectal ultrasound.
▪ This trial can suggest the possibility of a new
treatment for faecal incontinence.
▪ The sample size of this study has a limitation
regarding power of observation, because this
study is a pilot randomised controlled trial.
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neurological insufﬁciency of the anal sphincter.
Treatment of faecal incontinence has been performed
by conservative or surgical treatments. Medical therapies
using bulking or constipating agents as well as biofeed-
back have been used for mild symptoms of faecal incon-
tinence.5 6 Sacral nerve stimulation was developed to
enforce neuromodulation of the anal sphincter using
implantable devices.7 In those with sphincter injuries
and severe symptoms, surgical treatment such as sphinc-
teroplasty, muscle transposition, artiﬁcial bowel sphinc-
teroplasty and faecal diversions, have so far been
performed. However, because these treatments are still
controversial in effectiveness, regenerative treatment of
the anal sphincter has been developed using mesenchy-
mal stem cells. Since mesenchymal stem cells have pluri-
potent abilities to differentiate into osteocytes, myocytes,
chondrocytes and adipocytes, they are regarded to have
beneﬁts to improve muscle contractile function by tissue
regeneration.8
There have been several efforts to treat faecal incon-
tinence by using mesenchymal stem cells.8–12 Frudinger
et al used an autologous muscle-derived cell injection to
treat anal incontinence that had developed from obstet-
ric trauma. According to their report, 10 women suffer-
ing from anal incontinence showed safety and improved
symptoms after an injection of autologous myoblast.9 In
the 5-year follow-up, there was improvement of anal
incontinence as well as quality of life.11
Recently, human adipose-tissue-derived mesenchymal
stem cells (ASCs) have been used for treatment of peri-
anal ﬁstulas, including Crohn’s disease.12 13 In phase II
clinical trials of Crohn’s ﬁstulas, autologous ASCs
demonstrated favourable therapeutic outcomes.13
Moreover, adipose-tissue has the beneﬁt of obtaining
higher rates of mesenchymal stem cells and is more
available than other bodies. Since ASCs have the abilities
of both suppression of the inﬂammatory response and
differentiation, it has potential beneﬁts to repair
damaged tissues.14 In these aspects of stem cell regener-
ation, we can hypothesise that ASCs can be used to treat
a degenerated anal sphincter that is causing faecal
incontinence. Therefore, this study aimed to investigate
the safety and efﬁcacy of allogeneic-adipose-derived mes-
enchymal stem cell (ALLO-ASC) injection into the anal
sphincter in patients with faecal incontinence as a phase
I clinical trial.
METHODS AND ANALYSIS
Study design
This study is a prospective, randomised, dose escalation,
placebo-controlled, single-blinded, single-centre, phase I
clinical trial with two parallel groups. It is being con-
ducted in Gangnam Severance Hospital, Yonsei
University College of Medicine in Seoul, Korea. This
trial is registered with ClinicalTrial.gov (NCT02384499).
The total study period is 2 years, from December 2014
to November 2016.
The study is composed of a safety test and an efﬁcacy
test. The safety test is carried out by dose escalation of
ALLO-ASC. ALLO-ASCs are injected into the anal
sphincter, using three different amounts. The patients in
group 1 will receive 3×107 cells, with 6×107 cells for
group 2 and 9×107 cells for group 3, sequentially. After
completing the safety test, a safe dose with the most
effective clinical outcomes will be determined by asses-
sing the changes of the Wexner score, the pressure of
the anal sphincter and the score of patients’ satisfaction.
After analysing the average values of these parameters in
each group, the dose that has the highest change with
statistical signiﬁcance will be determined for the efﬁcacy
test.
The efﬁcacy test is performed by comparing the
experimental group and the placebo group. The six
patients in the experimental group will receive
ALLO-ASC injection mixed with ﬁbrin glue (Greenplast,
Seoul, Korea) into the anal sphincter, while the six
patients in the placebo group will receive 0.9% normal
saline injection mixed with ﬁbrin glue. The detailed
trial ﬂow is described in ﬁgure 1.
Study population
Inclusion criteria
▸ Participants at least 19 years old
▸ Patient received previous treatments for faecal incon-
tinence, such as medical therapy, biofeedback or
sacral nerve stimulation of more than 2 months, with
a Wexner score ≥8
▸ Transanal ultrasonography: presents a continuous
pattern of the anal sphincter
▸ Anal manometry: decreased anal pressures are less
than normal level
▸ Patients are negative for urine β-human chorionic
gonadotropin in the screening test
▸ An informed consent form has been signed by the
patient
Exclusion criteria
▸ Participation in another clinical trial within the past
30 days
▸ History of anorectal surgery within the previous
6 months
▸ History of malignant tumour surgery within the previ-
ous 5 years
▸ Patients requiring anorectal surgical treatments
▸ History of artiﬁcial sphincter surgery
▸ History of vaginal delivery within the past 6 months
▸ Medical history of variant Creutzfeld-Jakobs disease
or related diseases
▸ Allergy to bovine-derived materials, ﬁbrin glue or
anaesthetics
▸ Autoimmune disease
▸ Active tuberculosis
▸ Pregnancy or breastfeeding women
▸ Unwillingness to use contraceptive methods
▸ Patients with inﬂammatory bowel disease
2 Park EJ, et al. BMJ Open 2016;6:e010450. doi:10.1136/bmjopen-2015-010450
Open Access
▸ Alcohol or drug abusers
▸ Use of cytotoxic agents within the past 30 days
▸ Patients who have severe constipation (<2 times/
week), anal ﬁstula, rectal prolapse, spinal cord injury,
multiple sclerosis and Parkinson’s disease
▸ Patients with haematological diseases, immunodeﬁ-
ciency, fever, acute disease or severe chronic disease
Owing to this study aims to investigate the regenerative
effects of ALLO-ASCs on the anal sphincter, we exclude
patients who have had previous anal sphincter injuries
or who had undergone anal surgeries that involved the
anal sphincter, before this trial. Patients who need to
treat a perianal disease or who have a comorbid disease,
which can be confounding factors, have also been
excluded. In addition, patients with a history of malig-
nant tumour, inﬂammatory bowel disease or pregnancy,
are excluded.
Screening and implementation
Before enrolment, the investigator assesses the eligibility
of potential participants according to the inclusion and
exclusion criteria. After getting informed consent, the
screening tests are performed in an outpatient clinic.
The detailed screening items to assess in the participants
are described below.
Screening items assessed by an investigator:
1. Patient characteristics
▸ Medical and concomitant drug histories
▸ Physical examination and vital signs
▸ Blood samplings for serological test, such as
complete blood count, biochemical test, ABO
typing, HBV surface antigen, hepatitis C virus,
HIV and Venereal Disease Research Laboratory
▸ Urinalysis including urine β-hCG
▸ Digital rectal examination
2. Objective outcome measures
▸ Wexner score
▸ Anorectal manometry
▸ Endorectal ultrasound
ALLO-ASC injection into the anal sphincter should be
performed within 1 month from the screening test. On
the day of surgical intervention, the investigator again
conﬁrms the eligibility of participants. Then, the partici-
pants will have a serological test, urinalysis, immuno-
logical test (CD4/CD8), digital rectal examination and
Wexner score (table 1), before the ALLO-ASC injection.
All detailed procedures are described in table 2.
Sample size and randomisation
Since this trial is a phase I pilot study, each group is
composed of three patients, to examine the safety of the
ALLO-ASC injection according to dose escalation. The
sample size of the safety test was based on the traditional
3+3 dose escalation design.15 In the efﬁcacy test, sample
size calculation was based on the assumption that the
standard variation of the Wexner score between the
Figure 1 Trial schema.
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experimental and the control group was 8. Then the
sample size was determined by α value of 0.05, β value
of 0.2, and a statistical power of 0.8 with 2-sided p values
using the PASS 14 software (NCSS LLC, Kaysville, Utah,
USA). Therefore, there are totally 12 patients, and each
group has 6 patients chosen by randomisation.
Randomisation is preceded by the SAS V.9.1 (SAS Inc,
Cary, North Carolina, USA) to generate random
numbers. After registration, an investigator randomises
and assigns the participants to an experimental or a
placebo group by a single-blinded design.
Statistical analysis
All patients who enrol in this trial are treated with an
intention-to-treat analysis. Per-protocol analysis is used to
evaluate the efﬁcacy of included patients who received
ALLO-ASC injections and completed visiting schedules.
The different results between the screening and
follow-up period during the safety test are analysed by
the student t test, χ2 test or Fisher’s exact test. The differ-
ences of the Wexner score, anorectal manometry, endor-
ectal ultrasound, patient satisfaction survey (table 3) and
faecal incontinence quality of life instrument (FIQL),16
Table 2 Schedule of enrolment, intervention and assessment
Study period
Process Screening and Enrolment Allocation
Postallocation
period (weeks)
Follow-up period
(months)
Timepoint −30 days 0 3 h 1 4 8 4 6 9 12
Enrolment and screening
Eligibility screening X X
Informed consent X
Medical or drug history X
Physical examination/vital signs X X X X X X X X X
Urine β-hCG* X X X
Serological and biochemical tests X X X X X
Urinalysis X X X X X
ABO Rh X
HBsAg X
HCV & HIV X
VDRL X
Digital rectal examination X X X X X X X X X X
Intervention
ALLO-ASC injection† X
Assessment
Local tolerability X X X X X X X X
Immunological test (CD4/CD8) X X X
Wexner score X X X X X X X X X
Anorectal manometry X X X X X X X
Endorectal ultrasonography X X X
Patient satisfaction survey X X X X X X
FIQL X X X X X X X
Stool diary X X X X X X X X X
Adverse events X X X X X X X X
Concomitant medications X X X X X X X X X
*Performed in fertile women.
†In the dose-escalation test, ALLO-ASCs are injected. In the efficacy test, a mixed solution of ALLO-ASCs with fibrin glue is injected in the
experimental group.
ALLO-ASC, allogeneic-adipose-derived mesenchymal stem cells; β-hCG, β-human chorionic gonadotropin; HBsAg, HBV surface antigen;
HCV, hepatitis C virus; FIQL, Faecal Incontinence Quality of Life Instrument; VDRL, Venereal Disease Research Laboratory.
Table 1 Wexner score (Cleveland Clinic Continence Scoring System)
Items Pattern of incontinence Never Rarely Sometimes Usually Always
1 Solid 0 1 2 3 4
2 Liquid 0 1 2 3 4
3 Gas 0 1 2 3 4
4 Wears pad 0 1 2 3 4
5 Lifestyle alteration 0 1 2 3 4
Never (0); Rarely (<1/month); Sometimes (<1/week, ≥1/month); Usually (<1/day, ≥1/week); Always (≥1/day); 0, perfect approximately 20,
complete incontinence.
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between the experimental and placebo groups, are ana-
lysed by the t test or Wilcoxon rank sum test. All statis-
tical analyses are performed using the SPSS V.20.0 (SPSS
Inc, IBM Corp, Chicago, Illinois, USA) and SAS V.9.1
(SAS Inc, Cary, North Carolina, USA). p Value less than
0.05 is considered statistically signiﬁcant.
The characteristics of ALLO-ASCs
This study uses ALLO-ASCs, which are manufactured at
Anterogen Co, Ltd, and approved for clinical studies by
the Korean Food and Drug Administration (Approval
number: Clinical-839). The phenotypes of ALLO-ASCs
are characterised by positivity for CD73, CD90 and CD
105, and negativity for CD34, CD45, CD14, CD11b,
CD79α, CD19 and HLA-DR. According to the position
statement of the International Federation for Adipose
Therapeutics and Science (IFATS), and the
International Society for Cellular Therapy (ISCT),
ALLO-ASCs are plastic adherent ﬁbroblast-like cells that
can be differentiated into adipocyte, chondrocyte and
osteocyte. In the immunophenotype, stromal-associated
markers such as CD73 and CD90 are expressed.
However, the hematopoietic-associated markers such as
CD34 and CD45 are not expressed in ALLO-ASCs.
Preparation of ALLO-ASCs
After receiving informed consent, human subcutaneous
fat tissues are harvested from the healthy adult donor.
ALLO-ASCs are isolated from the lipo-aspirates of fat
tissues. In this study, the ALLO-ASCs made from the
same individual donors were used to maintain the con-
sistency of the stem cells. According to the ‘Guidelines
on the Requirements for Quality Dossier of Biological
Products in Clinical Trials’ of the Korean Ministry of
Food and Drug Safety (MFDS), donor suitability is
assessed.
The fat tissues, which were obtained from
lipo-aspirates, were washed with phosphate-buffered
saline (PBS) and digested in an equal volume of
0.025% collagenase type I (Invitrogen, Gaithersburg,
Maryland, USA) and PBS containing 1% bovine serum
albumin. We cultured the isolated stromal vascular frac-
tion in Dulbecco’s modiﬁed Eagle’s Medium (DMEM),
which is supplemented with 10% fetal bovine serum
(FBS) and 1 ng/mL human basic-ﬁbroblast growth
factor. Cells were harvested at 80% conﬂuence and
subcultured with 3 or 4 times of passage. After the cells
were harvested via trypsinisation, ALLO-ASCs were
packaged into single vials. The manufacturing process
was performed by following the Good Manufacturing
Practices of MFDS. Following these guidelines, before
releasing the ALLO-ASCs, ample testing to assess for
cell appearance, purity, viability, identiﬁcation, potency
and content is carried out. The safety of ALLO-ASCs
from accidental contamination during the procedure is
assessed by the test, for mycoplasma, viruses, bacteria
and fungi.
Intervention
This trial is based on the injection of ALLO-ASCs into
the anal sphincter in patients with faecal incontinence.
In the safety test, the investigator begins to inject
ALLO-ASCs into the anal sphincter of 3×107 cells, 6×107
cells and 9×107 cells in each group, sequentially. Fibrin
glue, which is composed of 3 mL of ﬁbrinogen and
0.8 mL of thrombin, is used to make a mixed solution of
ALLO-ASCs. The numbers of ALLO-ASCs in each group
are controlled by the concentration between a diluted
solution and ALLO-ASCs. The ﬁnal 6 mL of mixed solu-
tion is prepared for ALLO-ASC injection. Under spinal
anaesthesia, the patient is positioned into a jack-knife
position. Before injection, ALLO-ASCs are measured
and prepared in a 21 gauge needle according to the
experimental dose. After exposing the anal canal,
two-thirds of the ALLO-ASCs are evenly injected into the
internal anal sphincter in four directions (3, 6, 9 and 12
o’clock). The investigator performs a digital rectal exam-
ination to assess the condition of the injected anal
sphincter. Then, the remaining dose of ALLO-ASCs is
injected into the external anal sphincter, as demon-
strated in ﬁgure 2. All procedures of the safety test are
the same, except with a different dose of ALLO-ASCs
injection by dose escalation. After ﬁnishing the safety
test, the investigator assesses a safe dose that satisﬁes the
most effective clinical outcomes. Then, this determined
amount of ALLO-ASCs will be used in the experimental
group in the following efﬁcacy test.
In the efﬁcacy test, the investigator injects a 6 mL
mixed solution of ALLO-ASCs with ﬁbrin glue into the
anal sphincter of patients in the experimental group,
using a dual syringe injection kit. In the placebo group,
the patients are injected with 0.9% normal saline mixed
with ﬁbrin glue. In this study, ﬁbrin glue is used for the
mixed solution of ALLO-ASCs because it can sustain
functional survival of mesenchymal stem cells and facili-
tates cell attachment, proliferation, differentiation and
tissue formation as a cell delivery vehicle.17 18 However,
it is injected in the experimental and the control group,
to exclude its effect for the symptoms of faecal incontin-
ence. The injection techniques into the anal sphincter
are the same with the safety test above. Three hours
after the injection, the investigator performs a digital
rectal examination and assesses both local tolerability
and adverse events.
Table 3 Patient satisfaction survey
Question Answer Score
Are you satisfied with the quality of
your daily life after an injection of
ALLO-ASCs into the anal sphincter?
Excellent 1
Very
Good
2
Good 3
Fair 4
Poor 5
ALLO-ASC, allogeneic-adipose-derived mesenchymal stem cells.
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End points of the study
Primary end point
▸ To assess a safe dose of ALLO-ASCs injection in the
anal sphincter, using dose escalation
Secondary end points
▸ To compare the efﬁcacy of ALLO-ASCs injection with
ﬁbrin glue against 0.9% normal saline injection with
ﬁbrin glue
▸ To assess local tolerability and toxicity after
ALLO-ASC injection into the anal sphincter muscle
Safety assessment and reporting of adverse events
Adverse events and safety assessment are evaluated at
every visit after the ALLO-ASC injection. The investiga-
tor has a duty to report adverse events and protect
patients who participate in this trial. Adverse events and
their associations with injected materials are reported
according to the WHO toxicity scale. Severe adverse
events that result in life-threatening and prolonged dis-
abled conditions, should be reported to the IRB by the
investigator.
Drop out
Participants have the right to drop out of the trial at any
time without stating any reason. Moreover, the patients
may be dropped out because of medical or other
reasons as follows:
▸ By the investigator, for the participant’s health and
well-being
▸ Violation of selection standard
▸ ALLO-ASC injection is over 24 h after the production
date
▸ Owing to development of disease, which can affect
the results of the clinical trial
▸ Worsening of disease
▸ A situation that is related to the exclusion criteria.
Follow-up of study
The patient visits the outpatient clinic after intervention
at the postallocation period and the follow-up period.
During the postallocation period, patients are assessed
at the 1st, 4th and 8th weeks after intervention. In the
safety test, the patient is assessed for clinical efﬁcient
outcomes at the 8th week after intervention. Then,
patients are followed up at the 4th, 6th, 9th and 12th
months, additionally. The basic methods to evaluate
postintervention outcomes are similar between the safety
and efﬁcacy tests. Details of the examinations are sum-
marised as follows:
▸ Physical examination, vital signs, digital rectal examin-
ation, local tolerability, Wexner score, adverse events,
patient satisfaction survey and FIQL: every visit
▸ Serological and biochemical test, urinalysis: 8 weeks,
6th and 12th months
▸ Urine β-hCG: 8 weeks, 12th month
▸ Immunological test (CD4/CD8): 1st and 4th weeks
▸ Endorectal ultrasonography: 4th week and 12th
month
▸ Anorectal manometry: every visit from the 4th week
after intervention.
Data collection and monitoring
The committee supervises data collection and manage-
ment in all procedures during the trial. All data are col-
lected by an appointed researcher who is approved by
the committee. They are monitored by the Standard
Operating Procedures (SOPs) of the Korean Good
Clinical Practice (KGCP) and ICH guidelines. Interim
analysis is performed in the ﬁrst year to assess the safety
of ALLO-ASC injection into the anal sphincter.
Outcome assessment
In the safety evaluation, the toxicity grade is assessed by
the WHO toxicity scale. Immunological response is
examined by comparing CD4/CD8 ratio on the 1st and
4th weeks after the ALLO-ASC injection. In addition,
local tolerability is evaluated by whether there are clin-
ical signs of skin eruption, infection, immunological
reaction or carcinogenesis, by physical examination.
The improvement of clinical symptoms is assessed by
the Wexner score and FIQL. According to these ques-
tionnaires, conducted at every visit, the scores are com-
pared before and after injection. If the Wexner score
and FIQL both have statistically signiﬁcant differences in
their results at every visit or they are within normal range
after treatment, it is regarded as an improved status.
Endorectal ultrasonography is utilised to assess the
integrity of both external and internal anal sphincter,
and anatomical abnormalities of the anal canal. The
result is reported as a normal or an abnormal appear-
ance after the examination. On the other hand, anorec-
tal manometry is utilised to evaluate the functional
outcomes of the anal sphincter after ALLO-ASC injec-
tion. Resting pressure, squeezing pressure, rectoanal
inhibitory reﬂex (RAIR), rectal sensitivity and rectal
Figure 2 The site of ALLO-ASC injection in the anal
sphincter. IAS, internal anal sphincter; EAS, external anal
sphincter. Black arrow, the direction of the ALLO-ASC
injection.
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capacity, are assessed. Each factor is assessed for statis-
tical signiﬁcance comparing preinjection and postinjec-
tion of ALLO-ASC status in all patients.
The patient satisfaction survey is used to assess subject-
ive symptoms of each patient. The changes of the score
are compared throughout each visit statistically.
Ethics and dissemination
This trial is conducted following the Good Clinical
Practice guidelines and the principles of the Declaration
of Helsinki. This study will be disseminated in peer-
reviewed journals and presented at a colorectal
conference.
DISCUSSION
Faecal incontinence is a devastating condition that may
cause social isolation of a patient, and impairs their
quality of life by creating embarrassment and anxiety.
According to a cost analysis of faecal incontinence, it is
a substantial economic burden to society, averaging
$4110 per patient, annually.19 Furthermore, as ours is
becoming a progressively ageing society, the increased
incidence of faecal incontinence can have a negative
impact on the public health system. However, the efﬁ-
ciency of treatments for faecal incontinence, such as
medical therapy, biofeedback, sacral nerve stimulation
and sphincteroplasty, have so far been limited and unsat-
isfactory.20 In this respect, stem cell therapy has
emerged as a new treatment option for faecal incontin-
ence. Since the anal sphincter degenerates with age,
injection of mesenchymal stem cells into the anal
sphincter has the potential to improve contractility as
well as to enhance regeneration of the anal sphincter,
theoretically. There are several recent reports to support
the regenerative effect of mesenchymal stem cells on the
anal sphincter. According to the results of an experi-
mental model by Lorenzi et al,21 bone marrow-derived
mesenchymal stem cell injection improved muscle
regeneration and contractility function of the anal
sphincter. In a cryoinjured rat model, Kang et al8
reported that autologous muscle-derived stem cells
enhanced contractility of the anal sphincter and differ-
entiation of muscle masses at the stem cell injection
sites.
In this study, we use ALLO-ASCs, which are obtained
from human adipose tissue. ASCs are attractive cells
because they are pluripotent and available in large quan-
tities.22 Since MSCs can improve tissue repair though
cell replacement and enhance the microenvironment
through a paracrine effect, recent studies of autologous
ASCs for Crohn’s ﬁstula showed favourable therapeutic
outcomes in phase I and phase II studies.12 13 23–25
Garcia-Olmo et al24 reported that expanded ASCs com-
bined with ﬁbrin glue was effective and safe for a
complex perianal Crohn’s ﬁstula, in a phase II clinical
study. In addition, ASCs can help to regenerate anal
sphincter tissues because the paracrine effect of MSCs
differentiates it into tissue-speciﬁc cells by secreting
various cytokines, chemokines and growth factors such
as vascular endothelial growth factor-1, Insulin-like
growth factor-1 and epidermal growth factor.26 27 The
characteristics of ASCs, with self-renewal ability and
tissue regeneration, are expected to enhance the con-
tractility of the anal sphincter in patients with faecal
incontinence.
Previous autologous ASC studies were performed by
extraction of fat tissues by liposuction from each patient
to prepare injected ASCs. Since patients suffered from
painful and inconvenient procedures, previous clinical
trials using autologous ASCs for faecal incontinence
failed and were terminated due to insufﬁcient enrol-
ment (NCT01011686). In this study, we will use allogen-
eic mesenchymal stem cells, which are more convenient
to prepare than ASCs since they are readymade pro-
ducts. In addition, because faecal incontinence develops
mostly in elderly people due to degeneration of the anal
sphincter, ALLO-ASCs made from young, healthy
donors, have the advantage of isolating more vigorous
progenitor cells than autologous ASCs do.28 Moreover,
ALLO-ASCs have potential beneﬁts to get more robust
stem cells and a higher rate of both paracrine effect and
cell engraftment than autologous ASCs do.29 In these
aspects, the results of this study will have an impact on
treating faecal incontinence because ALLO-ASCs have
theoretical potential for regeneration of the anal
sphincter.
Regarding their immunological aspects, MSCs have
immunosuppressive properties that are transplantable in
patients with HLA-incompatibility.30 31 Le Blanc et al30
reported that MSCs do not lead to alloreactive lympho-
cyte proliferative responses as well as the modulation of
the immune response. The immunoprivileged character-
istics of MSCs in vitro can allow ALLO-ASCs in clinical
use.32 However, there has been a concern that allogeneic
MSCs can be altered from an immunoprivileged to an
immunogeneic condition by biphasic immune
response.29 In this study, the concentration of
ALLO-ASCs used for local injection is not adequate to
alter the immune response. Although there is a lack of
knowledge regarding long-term outcomes after using
ALLO-ASCs, we expect that an ALLO-ASC injection into
the anal sphincter is safe and feasible, and without an
immune response.
Malignant transformation of MSCs has been debated
because immunosuppressive characteristics of MSCs can
facilitate tumourigenesis.32 Rubio et al33 reported that
adipose tissue-derived MSCs could have immortalisation
and spontaneous transformation from long-term in vitro
expansion. However, there has so far been a lack of
research on the potential dangers of tumourigenicity
from MSCs. Further research on the long-term out-
comes of MSCs is necessary.
This study has the limitation of a small sample size in
a single centre, as it is a pilot randomised controlled
trial. Although the study population was determined by
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traditional 3+3 dose escalation and sample size calcula-
tion, it has a limitation to draw a general conclusion for
the effect of ALLO-ASCs. However, this study is the ﬁrst
clinical trial to use ALLO-ASCs in patients with faecal
incontinence. The results of this pilot study can contrib-
ute in determining a safe dose of ALLO-ASCs in clinical
use. In addition, it will be possible to expand it to future
clinical trials using ALLO-ASCs for the treatment of
faecal incontinence.
In conclusion, it is meaningful that our study is the
ﬁrst to investigate the effect of ALLO-ASCs for faecal
incontinence by a randomised, prospective clinical trial.
We expect that our results of this research can illuminate
more efﬁcient and convenient methods to overcome the
limits of previous treatments for faecal incontinence.
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